Palonosetron Stada

Palonosetron, the active ingredient in Palonosetron Stada, is a 5-HT3 receptor antagonist presented as a 0.075 mg injection for intravenous use. It is used to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonosetron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Palonosetron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron is indicated for the prevention of nausea and vomiting associated with chemotherapy and postoperative settings, acting on the serotonergic pathway.

- Chemotherapy‑induced nausea and vomiting (CINV): helps prevent acute and delayed episodes in adult patients receiving highly emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): reduces the incidence of nausea and vomiting after general anesthesia. - Radiotherapy‑induced nausea and vomiting: lessens nausea associated with moderate to high dose radiotherapy. - Anticipatory nausea: provides prophylactic benefit when patients expect nausea from prior treatment experiences. - Adjunct therapy in combination regimens: used alongside other antiemetics to improve overall control of emesis. - Supportive care : enhances patient comfort by prevent ​   ​  ​  ​  ​ ​  ​ ​  ​  ​